Preparation and in vitro evaluation of berberine hydrochloride nanoemulsion oral drug delivery systems
10.12206/j.issn.1006-0111.202107081
- VernacularTitle:盐酸小檗碱纳米乳口服给药系统的制备及体外评价
- Author:
Weili DAI
1
;
Ying JIN
1
;
Ting WANG
2
;
Xiaomeng TANG
3
;
Qing GU
1
Author Information
1. Department of Pharmacy, Zhabei Central Hospital of Shanghai Jingan District, Shanghai 200070, China.
2. School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China.
3. Department of Pharmacy, Changhai Hospital, Naval Military Medical University, Shanghai 200433, China.
- Keywords:
berberine hydrochloride;
nanoemulsion;
pseudoternary phase diagram;
central composite design-response surface method;
in vitro release
- From:
Journal of Pharmaceutical Practice
2022;40(1):28-33
- CountryChina
- Language:Chinese
-
Abstract:
Objective To prepare berberine hydrochloride nanoemulsion, optimize its formulation composition and preparation process, and investigate its in vitro characteristics. Methods BBR-NE was prepared by water drop addition and pseudo-ternary phase diagram was drawn. The formulation of NE was optimized by central composite design-response surface methodology to choose the optimal formulation composition. The particle size, potential and appearance of the prepared BBR-NE were characterized. Results The optimal prescription of BBR-NE was determined as the oil phase Capryol 90 accounted for 32.84% of the system, the surfactant Tween-80 accounted for 33.90%, the co-surfactant 1,2-propylene glycol accounted for 16.95%, and water relative system accounted for 15.25%. The prepared NE was clear and transparent in appearance, regular in shape and uniform in size, with an average particle diameter of (68.85±8) nm, polydiseperse index of (0.245±0.03) and drug loading of 0.83 mg/g. The in vitro drug release results of NE showed that the in vitro drug release behavior was passive diffusion, which had a certain slow releasing effect and met the first-order release equation. Conclusion The BBR-NE can provide a new dosage form for the clinical use of berberine.
